Morgan Stanley Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $182.00

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its price target lowered by analysts at Morgan Stanley from $196.00 to $182.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has an "overweight" rating on the biotechnology company's stock. Morgan Stanley's price objective would suggest a potential upside of 234.44% from the stock's previous close.

Other equities analysts have also issued research reports about the stock. Wells Fargo & Company began coverage on shares of Sarepta Therapeutics in a report on Friday. They set an "overweight" rating and a $115.00 price target on the stock. HC Wainwright upgraded Sarepta Therapeutics from a "sell" rating to a "neutral" rating and set a $75.00 price target on the stock in a research report on Wednesday, April 2nd. Needham & Company LLC lowered their price objective on Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating for the company in a research report on Thursday, April 3rd. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research report on Wednesday, March 19th. Finally, Scotiabank dropped their price target on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a research report on Thursday, March 20th. Six investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $161.83.

Remove Ads

Sarepta Therapeutics Trading Down 0.4 %

Shares of NASDAQ:SRPT traded down $0.21 during midday trading on Friday, hitting $54.42. 2,214,362 shares of the stock were exchanged, compared to its average volume of 1,395,801. The business's 50-day moving average price is $86.82 and its 200 day moving average price is $109.61. Sarepta Therapeutics has a 12 month low of $48.01 and a 12 month high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The stock has a market capitalization of $5.28 billion, a price-to-earnings ratio of 43.54 and a beta of 0.93.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 7.70% of the company's stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. boosted its holdings in Sarepta Therapeutics by 2.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company's stock worth $75,842,000 after buying an additional 12,000 shares during the period. Proficio Capital Partners LLC purchased a new position in shares of Sarepta Therapeutics in the fourth quarter valued at $3,829,000. Geode Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock valued at $211,910,000 after purchasing an additional 44,306 shares during the period. Nordea Investment Management AB boosted its position in shares of Sarepta Therapeutics by 19.1% in the fourth quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company's stock valued at $8,228,000 after acquiring an additional 10,815 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its holdings in Sarepta Therapeutics by 16,717.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company's stock worth $10,602,000 after acquiring an additional 84,926 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.